RESEARCH SUMMARY
Study Title: MatchMiner: An open-source AI precision medicine trial matching platform
Publication: AACR Presentation Number: 1067: Poster Board Number: 11, Section 43; Sunday, April 16, 1:30-5:00 pm.
Dana-Farber Cancer Institute author: Harry Klein, PhD
Summary:
A software platform that matches patients with appropriate clinical trials of targeted therapies has helped hundreds of patients at Dana-Farber enroll in such trials since the platform's launch in 2017. Called MatchMiner, it uses data on the genetic features of a patient's cancer, as well as clinical data, to identify trials at Dana-Farber Cancer Insitute for which the patient might be eligible. For clinical investigators hoping to enroll patients on a trial, MatchMiner can help recruit patients that meet the trial's eligibility requirements. At the AACR Annual Meeting, the platform's developers will present new information on 256 clinical trial consents facilitated by MatchMiner. Developers found, for example, that trial consents have been made for 20 cancer types and that 87% of patients who consented to join a clinical trial identified by MatchMiner actually participated in the trial. Because some patients are not ready to enroll in a targeted therapy trial because their cancer is responding to standard treatment or are in remission, the platform's developers and Dana-Farber's Kenneth Kehl, MD, MPH, are evaluating the use of artificial intelligence to identify patients at the time they are likely to need a new treatment option.
Impact:
MatchMiner, a software platform that matches patients with appropriate clinical trials of targeted therapies, has helped hundreds of patients at Dana-Farber enroll in such trials since the platform's launch six years ago. The platform's developers will present new information on the percentage of patients who consented to join a clinical trial identified by MatchMiner actually participated in the trial.
Developers found, for example, that trial consents have been made for 20 cancer types and that 87% of patients who consented to join a clinical trial identified by MatchMiner actually participated in the trial.